Entries |
Document | Title | Date |
20080234351 | Combination Methods for Preserving Visual Acuity - The present invention relates to a method for preserving the vision of a patient suffering from diabetic retinopathy which comprises administering to said patient an effective amount of ruboxistaurin or a pharmaceutical salt thereof wherein said administration is in conjunction with focal or grid laser photocoagulation therapy. | 09-25-2008 |
20080306131 | Progesterone receptor modulator and uses thereof - Compounds of the structure: | 12-11-2008 |
20090076115 | Photosensitizers for Targeted Photodynamic Therapy - The present invention relates to photosensitizer compounds based on functionalized fullerenes useful in targeted photodynamic therapy (PDT), and methods of use thereof. | 03-19-2009 |
20090131498 | Enantioselective Synthesis of Merrilactone and Its Analogs - This invention provides a method of synthesizing enantioenriched merrilactone A and enantiopure merrilactone A, as well as an improved method of synthesizing racemic merrilactone. This invention also provides intermediate compounds and methods of treating peripheral neuropathies | 05-21-2009 |
20090131499 | PHOTODYNAMIC THERAPY FOR SKIN RELATED PROBLEMS - PhotoDynamic Therapy method is used to treat problems associated with pilosebaceous units including acne and other skin conditions. At least one liposomal-formulated, hydrophobic photosensitizer, such as a dihydro- or tetrahydro-porphyrin, is topically applied to acne affected regions, and is allowed to penetrate the hair follicle before being irradiated with a suitable wavelength of light energy overlapping the absorption spectrum of the selected photosensitizer. The photoactivated agent initiates a cytotoxic effect in the sebaceous gland, reducing excess oil production and destroying bacterial growth in the follicle thus subsiding inflammatory action. Scarring of the skin is minimized and the skin heals faster due to collagen cell stimulation. | 05-21-2009 |
20090131500 | PORPHYRIN DERIVATES AND THEIR USE AS PHOTOSENSITIZERS IN PHOTODYNAMIC THERAPY - The present invention relates to novel porphyrin derivates of formula (I), especially to porphyrins which carry substituted phenyl moieties in meso-position. The porphyrin derivates of the invention are useful as photosensitizers in photodynamic therapy (PDT), especially in photodynamic tumor therapy. Due to their excellent photophysical properties the compounds of formula I are extremely efficient in photodynamic treatment. | 05-21-2009 |
20090143456 | Polyamine Analogs as Modulators of Cell Migration and Cell Motility - This disclosure relates to methods of inhibiting cell motility or cell migration, and of treating diseases involving cell migration or cell motility, using polyamine analogs, such as conformationally restricted polyamine analogs. The diseases to be treated include immune disorders, inflammatory conditions, infection, abnormal immune responses, undesired angiogenesis, tumor cell metastasis or invasion, atherosclerosis, vascular graft occlusion, transplant rejection, other complications of transplants, glomerulonephritis, arthritis, inflammatory responses subsequent to stroke or ischemia, and asthma. | 06-04-2009 |
20090143457 | POLYCYCLIC COMPOUNDS FOR USE IN TREATING OCULAR NEURODEGENERATIVE DISEASES - Described herein are various compounds for treatment of ocular neurodegenerative diseases, including but not limited to glaucoma and diabetic retinopathy. The compounds described herein can act to attenuate and/or block calcium release from external neuronal environments as well as intracellular stores. | 06-04-2009 |
20090149525 | NOVEL DERIVATIVES OF PORPHYRIN, PARTICULARLY CHLORINS AND/OR BACTERIOCHLORINS, AND USES THEREOF IN PHOTODYNAMIC THERAPY - The invention relates to derivatives of porphyrin, particularly chlorins and/or bacteriochlorins, which can be used in photodynamic therapy. According to the formulas of the invention, X | 06-11-2009 |
20090149526 | Tetracyclic Indole Derivatives as Antiviral Agents - The present invention relates to tetracyclic indole derivatives of formula (I): wherein Ar, A, R | 06-11-2009 |
20090149527 | Apparatus and Method for Application of a Pharmaceutical to a Surface of an External Ear Canal for Treatment of Keratosis Obutrans - A packaged kit for treating keratosis obturans includes a plurality of ear needles having different shaped absorbent applicators on distal ends of the needles, a vial of a single dose of an otologic formulation of mitomycin-C, and a diluent carrier syringe containing sterilized water. The component parts of the kit are used together to reconstitute the contents of the vial with the water in the diluent carrier syringe. A selected one of the plurality of ear needles is then communicated with the syringe. The syringe and needle are then used to inject the reconstituted drug into the absorbent pad at the end of the needle, and the absorbent pad containing the drug is used to apply the drug to the surface of the external ear canal. | 06-11-2009 |
20090176855 | TREATMENT OF BIPOLAR DISORDERS AND ASSOCIATED SYMPTOMS - The present invention relates to a method and kits for treating bipolar disorder in a mammal, including a human, the treatments including treatment of bipolar disorder including rapid-cycling, treatment of symptoms of bipolar disorder including acute mania or hypomania and depression, and episodes or occurrences including both acute mania or hypomania and depression; treatment for effecting mood stabilization; treatment for preventing relapse into bipolar episodes, and for the treatment of suicidal thoughts and tendencies associated with bipolar disorder, comprising administering to said mammal an effective amount of a compound of Formula | 07-09-2009 |
20090192209 | Extended treatment of tumors through vessel occlusion with light activated drugs - Methods of treating diseases of a subject through selective occlusion of blood vessels. The methods include identifying and/or mapping the blood vessels supplying nutrients to the diseased or unwanted tissue, delivering an appropriate dose of an occlusion-forming photosensitizer to the subject, and exciting the photosensitizer with sufficient light irradiation in the vicinity of the blood vessels to cause vessel occlusion. The vessel occlusion cuts off nutrient supply to the diseased or unwanted tissue resulting in cell death of that tissue and any other tissue served by the occluded vessels. | 07-30-2009 |
20090203757 | ETHYLENE GLYCOL ESTERS AS PHOTOACTIVE AGENTS - New compounds useful in photodynamic therapy are of the formula | 08-13-2009 |
20090209608 | DEUTERIUM-ENRICHED ASENAPINE - The present application describes deuterium-enriched asenapine, pharmaceutically acceptable salt forms thereof, and methods of treating using the same. | 08-20-2009 |
20090215851 | Method of Preparing a Porphyrin Derivative, a Porphyrin Derivative, Use of Said Porphyrin derivative and a pharmaceutical composition containing said porphyrin derivative - The present invention relates to a method of preparing a porphyrin derivative from a meso-acrylonitrile-substituted porphyrin compound. According to the invention a Vilsmeier reagent carrying an aromatic ring is used, wherein said Vilsmeier reagent is a soft electrophile. The use of this Vilsmeier reagent results in a porphyrin derivative having the ring system of the Vilsmeier reagent condensed to its porphyrin macrocycle via two new 6 membered rings. Thus a new class of porphyrin derivatives is provided, wherein said derivatives are photodynamically more active than the starting compound. The invention also relates to a porphyrin derivative, use of said porphyrin derivative and a pharmaceutical composition containing said porphyrin derivative. | 08-27-2009 |
20090264492 | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF A FUNGAL SKIN DISORDER AND A METHOD FOR THE PREPARATION THEREOF - The present invention relates to a pharmaceutical composition for photodynamic treatment of a fungal skin disorder, said pharmaceutical composition comprising a photosensitizer and an enhancer, wherein the photosensitizer is a cationic photosensitizer and the enhancer is chosen from the group of i) an acid, and ii) a metal chelating agent. Such a composition is capable of eliminating both conidiae and hy-phae. The invention also relates to a method for the preparation of the pharmaceutical composition. | 10-22-2009 |
20090291996 | Caspofungin free of caspofungin Co - The present invention provides Caspofungin and salts thereof substantially free of Caspofungin C | 11-26-2009 |
20100056599 | SUBSTITUTED INDENO[1,2-B]INDOLE DERIVATIVES AS NOVEL INHIBITORS OF PROTEIN KINASE CK2 AND THEIR USE AS TUMOR THERAPEUTIC AGENTS, CYTOSTATICS AND DIAGNOSTIC AIDS - Synthesis of novel substituted indeno[1,2-b]indole derivatives of the type of 5,6,7,8-tetrahydroindeno[1,2-b]indole-9,10-diones and 5H-indeno[1,2-b]indole-6,9,10-triones, which show pronounced inhibition of the human protein kinase CK2, and the use thereof as active ingredients in medicaments and/or drug products in particular for the treatment of neoplastic diseases. | 03-04-2010 |
20100076046 | Antiviral Indoles - Compounds of the formula (I) wherein A, B, D, M, Ar, W, X, Y, Z and R | 03-25-2010 |
20100093823 | STEROIDAL COMPOUNDS AS MELANOGENESIS MODIFIERS AND USES THEREOF - A method for the identification of compounds) that control melanin synthesis (melanogenesis), and the preparation and use of such compounds, and compositions and formulations thereof to modify (e.g., inhibit) melanin production are disclosed. A representative compound of the invention is defined by formula I: | 04-15-2010 |
20100113554 | MANUFACTURE AND PRODUCTS THEREOF OF PHOTOSENSITIZING NANOMATERIALS AND THEIR USE IN PHOTODYNAMIC TREATMENT - A method for the manufacture of a photosensitizing nanomaterial ( | 05-06-2010 |
20100137396 | TREATMENT OF ESOPHAGEAL HIGH GRADE DYSPLASIA USING PHOTODYNAMIC THERAPY - A method for treatment of esophageal high grade dysplasia comprising the steps of: injecting HPPH in a physiologically compatible medium into a patient having high grade dysplasia tissue to provide a dose level of 3 through 5 mg/m | 06-03-2010 |
20100144820 | THERAPEUTIC HPPH DOSAGE FOR PDT - A method for treating cancer and other hyperproliferative tissues in humans that can be exposed to light comprising injection of HPPH at the equivalent to a dose of 0.05 to 0.11 mg/kg of body weight 24 hours post injection and exposing the tumor or other hyperproliferative tissue to 665±10 nm of light at 50 to 200 Joules/cm | 06-10-2010 |
20100152267 | NOVEL RIFAMYCIN 3,4-(3-SUBSTITUTED AMINOMETHYL) FUSED PYRROLO DERIVATIVES - The present invention is directed to novel 3,4-(3′-substituted aminomethyl) fused pyrrolo rifamyacin derivatives, pharmaceutical compositions containing them and the use of said derivatives and pharmaceutical compositions as antimicrobial agents against pathogenic microorganisms, particularly against resistant microbes. | 06-17-2010 |
20100160403 | HCV NS3 PROTEASE INHIBITORS - The present invention relates to macrocyclic compounds of formula (Ia) that are useful as inhibitors of the hepatitis C virus (HCV) NS3 protease, their synthesis, and their use for treating or preventing HCV infections. | 06-24-2010 |
20100184818 | PHOTOSENSITIZERS FOR TARGETED PHOTODYNAMIC THERAPY - The present invention provides photosensitizer compounds based on functionalized fullerenes useful in targeted photodynamic therapy (PDT), and methods of use thereof. | 07-22-2010 |
20110009464 | IMMUNE SYSTEM STIMULATION BY LIGHT THERAPY INDUCED APOPTOTIC CELL DEATH IN ABNORMAL TISSUE - The efficacy of light activated therapy treatment is enhanced by stimulating the immune system of the patient substantially above the pre-therapy level. Abnormal tissue that is destroyed by the light activated therapy releases factors that stimulate the immune system, leading to systemic reductions in abnormal tissue (i.e., reduction beyond the area treated using light), so long as the light therapy conditions favor apoptosis over necrosis. The volume of abnormal tissue destroyed is maximized to the extent possible, reducing tumor load, which reduces an amount of immunosuppressive factors in the body, enabling stimulation of the immune system to be successful. | 01-13-2011 |
20110054001 | CHK1 SUPPRESSES A CASPASE-2 APOPTOTIC RESPONSE TO DNA DAMAGE THAT BYPASSES P53, BCL-2 AND CASPASE-3 - The invention describes methods that are useful for treating cancer by administering a Chk1 inhibitor which can induce apoptosis in p53-defective cells when combined with a chemotherapy and/or radiotherapy. Methods for screening candidates for a Chk1 inhibitor-based cancer treatment regimen are also described. | 03-03-2011 |
20110166194 | Asenapine Prodrugs - Compounds of Formula I and their use for the treatment of neurological and psychiatric disorders including schizophrenia and manic or mixed episodes associated with bipolar I disorder with or without psychotic features is disclosed: | 07-07-2011 |
20110263669 | Novel Pyrrolo [2,3-A] Carbazoles and Use Thereof as PIM Kinase Inhibitors - The invention relates to pyrrolo[2,3-a]carbazole derivatives, to a method for preparing the same, and to the use thereof as PIM kinase inhibitors. The invention can particularly be used in the pharmaceutical field. | 10-27-2011 |
20110269810 | SELECTIVE INHIBITORS OF C-JUN N-TERMINAL KINASE - Compositions and methods for treating, preventing, or ameliorating one or more symptoms, disorders, or conditions associated with particular c-Jun N-terminal kinase(s) (JNKs) activity are provided. Compositions contain small molecules such as pyrazoloanthrones. | 11-03-2011 |
20110275686 | NANOPARTICLE CARRIER SYSTEMS BASED ON POLY(DL-LACTIC-CO-GLYCOLIC ACID) (PLGA) FOR PHOTODYNAMIC THERAPY (PDT) - Compositions, which are stable in storage, and a method of production of pharmaceutical based nanoparticulate formulations for clinical use in photodynamic therapy comprising a hydrophobic photosensitizer, poly(lactic-co-glycolic) acid and stabilizing agents are provided. These nanoparticulate pharmaceutical formulations provide therapeutically effective amounts of photosensitizer for parenteral administration. In particular, tetrapyrrole derivatives can be used as photosensitizers, whose efficacy and safety are enhanced by such nanoparticulate formulations. It also teaches the method of preparing PLGA-based nanoparticles under sterile conditions. In one of the preferred embodiments of the present invention PLGA-based nanoparticles have a mean particle size less than 500 nm and the photosensitizer is temoporfin, 5,10,15,20-tetrakis(3-hydroxyphenyl)-chlorin (mTHPC). In another embodiment, the photosensitizer 2,3-dihydroxy-5,10,15,20-tetrakis(3-hydroxyphenyl)-chlorin (mTHPD-OH) is formulated as a nanoparticle for parenteral administration. Yet, in another embodiment preferred photosensitizer is 5,10,15,20-tetrakis(3-hydroxyphenyl)-porphyrin (mTHPP). The formulations can be used for treating hyperplasic and neoplasic conditions, inflammatory problems, and more specifically to target tumor cells. | 11-10-2011 |
20120015998 | PHOTOTHERAPY METHODS AND DEVICES COMPRISING EMISSIVE ARYL-HETEROARYL COMPOUNDS - Disclosed herein are compounds represented by a formula: R | 01-19-2012 |
20120029045 | METHOD FOR TREATING PORT WINE STAINS - A method of using photodynamic therapy to perform selective targeted therapy of biological tissue. The method includes intravenously injecting a porphyrin-based photosensitizing drug followed by irradiating the tissue with light while the drug is being injected. The duration of the irradiation and other parameters are controlled so that the selected biological tissue is treated and non-selected tissue is not damaged. By controlling the flow rate of the injection and other parameters, so that irradiation of the effected tissue overlaps with injection of drug, the target tissue is effectively treated without damage to non-target tissue. | 02-02-2012 |
20120136037 | DEUTERIUM-ENRICHED RUBOXISTAURIN - The present application describes deuterium-enriched ruboxistaurin, pharmaceutically acceptable salt forms thereof, and methods of treating using the same. | 05-31-2012 |
20120184590 | FORMULATIONS OF INDOLE-3-CARBINOL DERIVED ANTITUMOR AGENTS WITH INCREASED ORAL BIOAVAILABILITY - A pharmaceutical composition for treating, inhibiting, or preventing cancer can include an indole-3-carbinol derivative compound in a pharmaceutically acceptable carrier that is configured for oral administration. The indole-3-carbinol derivative compound can have antitumor activity, and oral administration can provide blood bioavailability of about 0.5% to about 25%. The pharmaceutically acceptable carrier can include a hydroxyl-fatty acid PEG monoester and/or diester. The carrier can be a hydroxyl-fatty acid PEG ester that includes 12-hydroxy stearate. The carrier can be a hydroxyl-fatty acid PEG ester that includes a PEG having from about 100 MW to about 200,000 MW. The indole-3-carbinol derivative can be 2,10-dicarbethoxy-6-methoxy-5,7-dihydro-indolo-(2,3-b)carbazole. | 07-19-2012 |
20120232121 | USE OF SARCOPLASMIC CA2+-ATPASE TYPE 2 PROTEIN FOR DIAGNOSING AND TREATING LEARNING OR MENTAL DISORDERS - The present invention embraces methods for the diagnosis and treatment of learning or mental disorders, as well as the identification of agents useful in the treatment of such disorders based upon the identified involvement of Sarcoplasmic Ca | 09-13-2012 |
20120258993 | NON-NATURAL MACROCYCLIC AMIDE HDAC6 INHIBITOR COMPOUNDS AND THEIR USES AS THERAPEUTIC AGENTS - The present invention relates to novel amide compounds of formula I, and their use as anti-tumoral and pro-apoptotic agents. The invention includes the use of such compounds in medicine, in relation to cancer disease as well as other diseases where an inhibition of HDAC6 is responsive, and the pharmaceutical composition containing such compounds. | 10-11-2012 |
20120264802 | PHOTOSENSITIZERS FOR TARGETED PHOTODYNAMIC THERAPY - The present invention relates to photosensitizer compounds based on functionalized fullerenes useful in targeted photodynamic therapy (PDT), and methods of use thereof. | 10-18-2012 |
20130065932 | PROCESS FOR THE ISOLATION OF ORGANIC COMPOUNDS USEFUL FOR THE TREATMENT OF CANCER - The present invention relates to two main components, mahanine and mahanimbine (dehydroxy-mahanine) from | 03-14-2013 |
20130079380 | Method and Composition for Administering Bioactive Compounds Derived From Morinda Citrifolia - This invention relates to a method and composition for providing in various health benefits by administering various bioactive compounds derived from the plant | 03-28-2013 |
20130116297 | NOVEL FUSARISETIN COMPOUNDS, AND USE THEREOF - The present invention relates to novel fusarisetin compounds separated from | 05-09-2013 |
20130172396 | USE OF DERIVATIVES OF PENTAPHYRINE AS ANTIMICROBIAL AND DISINFECTANT AGENTS - The invention relates to the use of 20-(4-carboxyphenyl)-2,13-dimethyl-3,12-diethyl-[22] pentaphyrine as antibacterial agent in photodynamic treatment. This expanded porphyrin derivatized in position 4 with a carboxyphenyl group proved very active after photo-oxidation both against | 07-04-2013 |
20130178508 | COSMETIC COMPOSITION - A highly moisturizing cosmetic composition having firmness/elasticity-improving effect, wrinkle-improving effect, and texture-improving effect can be provided by blending a metal phthalocyanine derivative or salt thereof in a cosmetic material. For the metal phthalocyanine derivative, iron phthalocyanine tetracarboxylic acid is particularly favorable. | 07-11-2013 |
20130267574 | Polymorphic Forms of Asenapine Maleate and Processes for their Preparation - Are disclosed new crystalline forms of asenapine maleate, useful in the production of pharmaceutical formulations for the treatment of diseases of the central nervous system, in particular schizophrenia; processes for the production of these new crystalline forms are also disclosed. | 10-10-2013 |
20130289089 | Pharmaceutical Compositions for Topical Delivery of Photosensitizers and Uses Thereof - The invention includes and provides compositions comprising photo | 10-31-2013 |
20130324582 | METHODS AND COMPOSITIONS FOR REDUCING FUNGAL INFESTATION AND IMPROVING GRASS QUALITY - Methods for reducing fungal infestation to a crop or plant by applying a composition including a dithiine-tetracarboximide compound to a crop or plant are described herein. Methods of reducing brown patch and/or dollar spot infestation to a plant or crop are also described herein. The disclosure also provides for methods of improving turfgrass and/or ornamental grass quality. | 12-05-2013 |
20130345278 | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATMENT AND PREVENTION OF ORTHOPOXVIRUS INFECTIONS AND ASSOCIATED DISEASES - Methods of using di, tri, and tetracyclic acylhydrazide derivatives and analogs, as well as pharmaceutical compositions containing the same, for the treatment or prophylaxis of viral infections and diseases associated therewith, particularly those viral infections and associated diseases caused by the orthopoxvirus. | 12-26-2013 |
20140011854 | ST-246 Liquid Formulations and Methods - The present invention provides for a novel liquid formulation for solubilizing poorly soluble ST-246 in cyclodextrins and a novel process of making the formulation. | 01-09-2014 |
20140051741 | CRYSTALLINE SALTS OF ASENAPINE - Disclosed is asenapine phosphate of formula (I) and its enantiomer (I) which can be used to prepare asenapine maleate. Further disclosed is a monoclinic crystalline form of asenapine maleate. | 02-20-2014 |
20140121259 | NOVEL CRYSTALLINE ASENAPINE HYDROCHLORIDE SALT FORMS - Novel crystalline HCl salts of Asenapine, methods of their preparation and related pharmaceuticals and treatments are disclosed. | 05-01-2014 |
20140128444 | NOVEL CRYSTALLINE SALTS OF ASENAPINE WITH ORGANIC DI-ACIDS AND TRI-ACIDS - Novel crystalline salts of Asenapine (I) with organic di-acids and tri-acids and to methods of their preparation are disclosed along with related pharmaceutical compositions and methods of treating psychotic diseases or disorders. | 05-08-2014 |
20140142157 | EXTRACT OF ASPLENIUM NIDUS L. - An extract of | 05-22-2014 |
20140142158 | STABLE MICRONISED MONOCLINIC FORM OF ASENAPINE MALEATE AND ITS SYNTHESIS - A stable micronised monoclinic form of asenapine maleate is described, which comprises 5% by weight or less of orthorhombic form or any other crystalline form of asenapine maleate, wherein the asenapine maleate has a particle size distribution characterised by a d90 equal to or below 40 μm. Processes for preparing the stable micronised monoclinic form of asenapine maleate are also described. Formula (I). | 05-22-2014 |
20140163083 | NOVEL CRYSTALLINE SALTS OF ASENAPINE - Crystalline Asenapine salts of tartaric acid or succinic acid, wherein the salts are e.g. selected from the group consisting of Asenapine D, L-tartrate hydrate form A, Asenapine D, L-tartrate hydrate form B, Asenapine D, L-tartrate anhydrous form, Asenapine succinate form X, Asenapine succinate form, and Asenapine succinate form II are described as well as related pharmaceutical compositions and related treatment of psychotic diseases or disorders. | 06-12-2014 |
20140371286 | DE NOVO SYNTHESIS OF BACTERIOCHLORINS - A method of making a bacteriochlorin is carried out by condensing a pair of compounds of Formula II | 12-18-2014 |
20150087685 | Phototherapy Devices and Methods Comprising Optionally Substituted Quinquiesphenyl Compounds - Methods and devices related to the treatment of diseases using phototherapy are described. Some embodiments provide an organic light-emitting diode device, such as a light-emitting device for phototherapy, comprising Ring System 1, Ring System 2, Ring System 3, Ring System 4 or Ring System 5. Methods of treating disease with phototherapy are also described. | 03-26-2015 |
20150094351 | COMPOSITION FOR TOPICAL USE - The use, as a dermatological or cosmetic medicament, of compounds capable of transiently interacting with the AhR receptor (aryl hydrocarbon receptor) as agents for modulating skin functions such as sebaceous function, skin healing, skin atropy termed “dermatoporosis”, estrogen deprivation and defense against infection, without inducing other toxic effects of the TCDD type. | 04-02-2015 |
20150141478 | SERIES OF DRUGS USING PHOTOFRIN TO CATALYZE DECOMPOSITION OF HYDROGEN PEROXIDE - The present invention relates to a series of new drugs which refer to chemical series capable of catalyzing the decomposition of H | 05-21-2015 |
20150328163 | ORALLY DISINTEGRATING TABLET CONTAINING ASENAPINE - The present invention relates to an orally disintegrating tablet (ODT) containing asenapine maleate and to a process for preparing the ODT. In a first aspect, the present invention relates to an ODT containing asenapine maleate and low substituted hydroxypropylcellulose. In a second aspect, the present invention relates to an ODT containing crystalline asenapine maleate and the ODT is prepared using conventional tabletting techniques as direct compression and granulation. In a third aspect, the present invention relates to an ODT containing asenapine maleate and a carboxylic acid, and to the use of a carboxylic acid for enhancing storage stability of an asenapine maleate containing ODT. | 11-19-2015 |
20150336973 | MONOCLINIC CRYSTALLINE FORM OF ASENAPINE MALEATE WITH A SPECIFIC PARTICLE SIZE DISTRIBUTION - A monoclinic crystalline form of asenapine maleate is described, which is characterized in that it is not micronised and has a particle size distribution characterized by a d90 of 40 μm or less. A process for the preparation of a monoclinic crystalline form of asenapine maleate is also described, the process comprising the following steps: a) providing a mixture of monoclinic asenapine maleate and an organic solvent which, under the conditions of the process, acts as an antisolvent; b) stirring the mixture at a temperature between 15 and 60° C.; and c) collecting the crystals, wherein the organic solvent is selected from alcohols, ketones, ethers, esters, hydrocarbons or mixtures thereof. | 11-26-2015 |
20160032406 | Diagnostic Method Using PALB2/US - The present invention provides a method for detecting mutations in the PALB2 gene in pancreatic cancer patients and in individuals having a family history of pancreatic cancer. Methods are also provided for diagnosing a predisposition to pancreatic cancer, for predicting a patient's response to pancreatic cancer therapies, and for treating pancreatic cancer, based on presence of a PALB2 mutation or abberant PALB2 gene expression in a patient. | 02-04-2016 |
20160082128 | ST-246 LIQUID FORMULATIONS AND METHODS - The present invention provides for a novel liquid formulation for solubilizing poorly soluble ST-246 in cyclodextrins and a novel process of making the formulation. | 03-24-2016 |
20160152565 | AMORPHOUS TECOVIRIMAT PREPARATION | 06-02-2016 |
20180021306 | INHIBITION OF YAP FOR BREAKING TUMOR IMMUNE TOLERANCE | 01-25-2018 |